Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Chirayu Auewarakul, Wipada Chartisathian, Thitikan Jansala, Rattana Julsawad, Kamonwan Soonklang, Nithi Mahanonda, Chulabhorn Mahidol
Phytomedicine, doi:10.1016/j.phymed.2023.155018
Background: While favipiravir had been the standard anti-SARS-CoV-3 drug for COVID-19 treatment in Thailand, the efficacy of favipiravir treatment is controversial. Andrographis paniculata extract (APE) inhibits viral entry, exhibits immunomodulatory effects, and proposes to have the potential for early-stage COVID-19 treatment. Methods: A randomized, double-blind, placebo-controlled trial was performed in Thailand during June -September 2021. Non-severe COVID-19 patients were randomized 1:1 to groups receiving 180 mg/day of APE plus favipiravir (APE-FPV group) or placebo plus favipiravir (placebo-FPV group). Efficacy in preventing disease progression to severe COVID-19 was assessed on day 4, using World Health Organization Clinical Progression Scale (WHO-CPS) score and visual analog scale (VAS) for acute respiratory tract infection symptoms. Results: Of 146 patients, there were 73 patients in each group. Non-deterioration of WHO -CPS scores on day 4 was 98.63% versus 97.26% of patients in the APE-FPV and placebo-FPV groups (p = 1.000). No difference in supplemental oxygen, hospitalization, and death was shown in both groups. The oxygen supplemental was 4.11% in the placebo-FPV group. The interleukin (IL)-1β was significantly lower in the APE than in the placebo-FPV group throughout the study. We found no difference in virologic outcomes between groups and no substantial adverse events. Conclusions: APE treatment did not demonstrate additional clinical and virological benefits in patients with mild to moderate COVID-19 being treated with favipiravir. Early reduction of IL-1β with APE may be advantageous in preventing cytokine storms in severe COVID-19 and requires further study.
Authors' contributions T.S. and N.M. had full access to all the data in this study and took responsibility for data integrity and accuracy. C.M., N.M., C.A., K.T., T. S., T.U., W.C., T.J., R.J., and K.S. contributed equally to the study.
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Taweegrit Siripongboonsitti reports financial support, administrative support, article publishing charges, equipment, drugs, or supplies, and statistical analysis were provided by Chulabhorn Royal Academy.
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.phymed.2023.155018.
References
Benjaponpitak, Visithanon, Sawaengtham, Thaneerat, Wanaratna, Short Communication on Use of Andrographis Herb (FA THALAI CHON) for the Treatment of COVID-19 Patients, J. Thai Tradit. Alternat. Med
Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N. Engl. J. Med,
doi:10.1056/NEJMoa2116044Caceres, Hancke, Burgos, Wikman, Prevention of common colds with Andrographis paniculata dried extract. A pilot double blind trial, Phytomedicine
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering (Beijing),
doi:10.1016/j.eng.2020.03.007Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of early treatment with favipiravir on disease progression among high-risk patients with coronavirus disease 2019 (COVID-19): a randomized, open-label clinical trial, Clin. Infect. Dis,
doi:10.1093/cid/ciab962Coon, Ernst, Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy, Planta Med
Dabbous, Abd-Elsalam, El-Sayed, Sherief, Ebeid et al., Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Arch. Virol,
doi:10.1007/s00705-021-04956-9Deng, Nie, Liu, Comparison of pharmacological effect of four andrographolides, Chinese Pharmaceut. Bull
Dey, Khanal, Patil, Wanjari, Srivast et al., The role of andrographolide and its derivative in COVID-19 associated proteins and immune system
Doi, Ando, Kuwatsuka, Ishihara, Favipiravir, Favipiravir observational study interim report 3
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin. Pharmacol. Therapeut,
doi:10.1002/cpt.1844Francone, Iafrate, Masci, Coco, Cilia et al., Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis, Eur. Radiol,
doi:10.1007/s00330-020-07033-yFuruta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad., Ser. B,
doi:10.2183/pjab.93.027Gabrielian, Shukarian, Goukasova, Chandanian, Panossian et al., A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis, Phytomedicine
Golan, Campos, Woolson, Cilla, Hanabergh et al., Favipiravir in patients with early mild-tomoderate COVID-19: a randomized controlled trial, Clin. Infect. Dis,
doi:10.1093/cid/ciac712Hammond, Leister-Tebbe, Gardner, Abreu, Bao et al., Oral nirmatrelvir for high-risk
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci. Rep,
doi:10.1038/s41598-021-90551-6Hsu, Chang, Shen, Chuang, Andrographolide and its derivatives as TNF-alpha antagonists
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial, Clin. Infect. Dis,
doi:10.1093/cid/ciaa1176Joshi, Vora, Venugopal, Dadhich, Daxini et al., Real-world experience with favipiravir for the treatment of mild-to-moderate COVID-19 in India, Pragmat Obs Res
Kligler, Ulbricht, Basch, Kirkwood, Abrams et al., Andrographis paniculata for the treatment of upper respiratory infection: a systematic review by the natural standard research collaboration, Explore: J. Sci. Heal
Lim, Chan, Tan, Teh, Mohd Abd Razak et al., Andrographis paniculata (Burm. F.) Wall. Ex Nees, andrographolide, and andrographolide analogues as SARS-CoV-2 antivirals? A rapid review,
doi:10.1177/1934578X211016610Madav, Tandan, Lal, Tripathi, Anti-inflammatory activity of andrographolide, Fitoterapia (Milano)
Madav, Tripathi, Mishra, Analgesic, antipyretic and antiulcerogenic effects of andrographolide, Indian J. Pharm. Sci
Mcmahon, Lau, Coldham, Roney, Hagenauer et al., Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2022.101703Nguyen, Corre, Honsel, Curac, Zarrouk et al., Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19, J. Infect,
doi:10.1016/j.jinf.2020.05.049Poolsup, Suthisisang, Prathanturarug, Asawamekin, Chanchareon, Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials, J Clin. Pharm. Ther
Qin, Kong, Shi, Wang, Ge, Andrographolide inhibits the production of TNF-α and interleukin-12 in lipopolysaccharide-stimulated macrophages: role of mitogen-activated protein kinases, Biol. Pharmaceut. Bull
Rehan, Ahmed, Howladar, Refai, Baeissa et al., A computational approach identified andrographolide as a potential drug for suppressing COVID-19-induced cytokine storm, Front. Immunol,
doi:10.3389/fimmu.2021.648250Romano, Ruggiero, Squeglia, Maga, Berisio, A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping, Cells,
doi:10.3390/cells9051267Sa-Ngiamsuntorn, Suksatu, Pewkliang, Thongsri, Kanjanasirirat et al., Anti-SARS-CoV-2 activity of andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives, J. Nat. Prod,
doi:10.1021/acs.jnatprod.0c01324Shen, Chen, Chiou, Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism (s) involved in its antiinflammatory effect, Br. J. Pharmacol
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol. J,
doi:10.1186/s12985-020-01412-zThamaree, Rugrungtham, Ruangrungsi, Thaworn, Kemsri, The inhibitory effects of extracts of some herbal medicines on the production of proinflammatory cytokines by in vitro stimulated human blood cells, Thai J. Pharmacol. S
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2020.11.142V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat. Rev. Microbiol,
doi:10.1038/s41579-020-00468-6Wagner, Cramer, Klose, Lauche, Gass et al., Herbal medicine for cough: a systematic review and meta-analysis, Compl. Med. Res
Wanaratna, Leethong, Inchai, Chueawiang, Sriraksa et al., Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: a randomized controlled trial
Weiss, Jellingsø, Sommer, WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, 2020. A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect. Dis,
doi:10.1016/s1473-3099(20)30483-7Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648Yearsley, Thailand approves asian herb Andrographis to treat COVID-19, HerbalGram
Zhang, Lv, Zhou, Xie, Xu et al., Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial, Phytother. Res,
doi:10.1002/ptr.7141Zhu, Zhang, Wang, Li, Yang et al., A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med,
doi:10.1056/nejmoa2001017
